drugset / Trial / NCT06837155

A QT/QTc Evaluation Study of TS-172 in Healthy Adult Subjects

NCT06837155

Phase 1 Completed 52 enrolled Taisho Pharmaceutical Co., Ltd.
RandomizedCrossoverQuadruple-blindTreatment

Summary

A clinical study to evaluate the effects on QT/QTc interval of TS-172 in healthy adults subjects

Timeline

Start
2025-03-03
Primary completion
2025-05-20
Completion
2025-05-26

Drugs

EvaluationDrugModalityDoseRoute
Comparator Moxifloxacin Small molecule 400 mg Oral
Subject TS-172 Unknown 20 mg Oral
Subject TS-172 Unknown 90 mg Oral

Indications

No indication recorded.